Published in BMC Cancer on May 01, 2015
When Is Rapid On-Site Evaluation Cost-Effective for Fine-Needle Aspiration Biopsy? PLoS One (2015) 0.81
Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing. Gynecol Oncol (2016) 0.78
Tumor-induced VEGF-C overexpression in retroperitoneal lymph nodes in VX2 carcinoma-bearing rabbits. Drug Des Devel Ther (2015) 0.78
Association of CCND1 gene polymorphism with cervical cancer susceptibility in Caucasian population: a meta-analysis. Int J Clin Exp Med (2015) 0.78
Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada. Curr Oncol (2016) 0.78
Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend. BMC Public Health (2017) 0.75
The cost-effectiveness of cervical self-sampling to improve routine cervical cancer screening: The importance of respondent screening history and compliance. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Influence of Human Papillomavirus Infection on the Natural History of Cervical Intraepithelial Neoplasia 1: A Meta-Analysis. Biomed Res Int (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med (2005) 6.72
Worldwide burden of cervical cancer in 2008. Ann Oncol (2011) 5.66
Recommendations on screening for cervical cancer. CMAJ (2013) 3.32
Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA (2001) 3.26
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09
Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine (2006) 1.71
Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer (2012) 1.69
Modeling cervical cancer prevention in developed countries. Vaccine (2008) 1.61
Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics (2006) 1.58
Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer (2011) 1.53
Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine (2008) 1.38
Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics (2009) 1.35
Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine (2013) 1.31
Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer (2008) 1.30
Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol (2014) 1.30
Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med (2009) 1.29
New technologies and procedures for cervical cancer screening. Vaccine (2012) 1.29
Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine (2006) 1.27
Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics (2011) 1.21
Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine (2012) 1.17
Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer (2011) 1.16
Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG (2011) 1.13
Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine (2011) 1.12
Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine (2012) 1.12
Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer (2010) 1.11
Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine (2012) 1.11
Modelling issues in cancer screening. Stat Methods Med Res (1995) 1.11
Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics (2011) 1.11
Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine (2012) 1.08
Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis (2014) 1.05
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ (2005) 1.01
Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. Health Technol Assess (2005) 0.99
Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis. Vaccine (2009) 0.99
Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine (2008) 0.98
Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol (2010) 0.89
Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG (2007) 0.86
[Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women: results of a Markov model from the public sector perspective]. Salud Publica Mex (2008) 0.86
Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era. J Public Health (Oxf) (2012) 0.85
Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine (2011) 0.85
Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. Womens Health Issues (2009) 0.83
Cost-effectiveness of pap smear screening for vaginal cancer after total hysterectomy for benign disease. J Low Genit Tract Dis (2003) 0.83
A systematic review of economic aspects of cervical cancer screening strategies worldwide: discrepancy between economic analysis and policymaking. Asian Pac J Cancer Prev (2014) 0.82
Mathematical models and natural history in cervical cancer screening. IARC Sci Publ (1986) 0.82
Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care (2008) 0.81
Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009. Clin Ther (2010) 0.80
Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol Oncol (2010) 0.80
Cost-effectiveness of cervical cancer prevention. Clin Obstet Gynecol (2013) 0.77
Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination. J Eval Clin Pract (2011) 0.77
Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors. Arch Fam Med (2000) 0.76